U.S. Appeals Court Affirms Medtronic's Willful Infringement of

U.S. Appeals Court Affirms Medtronic's Willful Infringement of
Edwards' Transcatheter Valve Patent 
IRVINE, CA -- (Marketwire) -- 11/13/12 --   Edwards Lifesciences
Corporation (NYSE: EW), the global leader in the science of heart
valves and hemodynamic monitoring, announced that the U.S. Court of
Appeals for the Federal Circuit today affirmed an April 2010 federal
jury decision that Medtronic CoreValve LLC is willfully infringing
Edwards' U.S. Andersen transcatheter heart valve patent. The Appeals
Court also ordered the trial court to reconsider Edwards' request for
a permanent injunction that would prohibit the manufacture and sale
of the CoreValve System in the United States. 
In addition, the Court affirmed the validity of this patent and the
federal jury's verdict awarding an initial payment of $74 million in
damages to Edwards, which covers infringement through early 2010.
Edwards anticipates that further proceedings by the U.S. District
Court for the District of Delaware will require Medtronic to pay
substantial additional damages accumulated after the verdict was
issued.  
"We are very pleased that the appeals court has confirmed that
Medtronic CoreValve is illegally using Edwards' transcatheter valve
technology. We believe this is a decisive milestone toward final
resolution of this matter, given that we have a clear jury verdict
that has been affirmed by both the District Court and now the U.S.
Court of Appeals," said Aimee S. Weisner, Edwards' corporate vice
president, general counsel.  
The patent involved in this suit is part of the Andersen family of
patents, which relates to a valve prosthesis for implantation by
means of a catheter. A petition has been filed with the United States
Patent and Trademark Office to extend this patent to 2017.  
About Edwards Lifesciences
 Edwards Lifesciences is the global leader
in the science of heart valves and hemodynamic monitoring. Driven by
a passion to help patients, the company partners with clinicians to
develop innovative technologies in the areas of structural heart
disease and critical care monitoring that enable them to save and
enhance lives. Additional company information can be found at
www.edwards.com.  
This news release includes forward-looking statements within the
meaning of Section 27A of the 
Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, statements made by Ms.
Weisner and statements regarding the outcome of future legal
proceedings and the expected patent term extension. Forward-looking
statements are based on estimates and assumptions made by management
of the company and are believed to be reasonable, though they are
inherently uncertain and difficult to predict. Our forward-looking
statements speak only as of the date on which they are made and we do
not undertake any obligation to update any forward-looking statement
to reflect events or circumstances after the date of the statement. 
Forward-looking statements involve risks and uncertainties that could
cause the outcomes to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors including but not limited to unexpected developments in the
patent office with respect to extension of the Andersen patent and
the unpredictability of future decisions at the trial court level.
These factors are detailed in the company's filings with the
Securities and Exchange Commission including its Annual Report on
Form 10-K for the year ended December 31, 2011. 
Edwards is a trademark of Edwards Lifesciences Corporation. Edwards
Lifesciences and the stylized E logo trademarks of Edwards
Lifesciences Corporation and are registered in the United States
Patent and Trademark Office.  
Media Contact: 
Sarah Huoh or Janet Kim 
949-250-5070 
Investor Contact: 
David K. Erickson 
949-250-6826 
 
 
Press spacebar to pause and continue. Press esc to stop.